文献速递肝病

非选择性β受体阻滞剂损害难治性腹水肝硬化患者循环稳态与肾功能

Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
PubMed 文献 · J Hepatol · 2020-05-21

该前瞻性前后重复测量研究纳入18例利尿剂应答性腹水和20例难治性腹水肝硬化患者,使用普萘洛尔4周后,难治性腹水患者EIVPD降低20%(DRA仅2%,p<0.01),肾灌注压和肾功能受损,55%患者肾灌注压降至肾血流自动调节阈值以下。结论提示难治性腹水患者应慎用或避免β受体阻滞剂。

要点

  • 难治性腹水患者基线EIVPD升高,与血管扩张和交感激活程度直接相关。
  • 普萘洛尔降低难治性腹水患者EIVPD 20%,利尿剂应答性腹水仅2%。
  • 难治性腹水患者用药后肾灌注压和肾功能受损,55%降至自动调节阈值以下。

核心结论

  • 难治性腹水患者的肾灌注和功能关键依赖收缩功能与交感过度激活,NSBBs削弱交感驱动、抑制心输出量、降低肾灌注压至临界阈值以下并损害肾功能。
  • β受体阻滞剂在难治性腹水患者中应谨慎使用甚至避免。

研究设计与样本

  • 前瞻性前后重复测量研究,纳入肝硬化患者,18例利尿剂应答性腹水(DRA)和20例难治性腹水(RA),均因食管静脉曲张出血预防使用NSBBs。
  • 在基线和普萘洛尔治疗4周后测量收缩功能(EIVPD)、HVPG、心肺压力、肾灌注压(RPP)和交感激活。

主要发现

  • 基线EIVPD升高:RA 4.5(2.8-5.7)mmHg,DRA 4.2(3.1-5.7)mmHg,正常范围2.4-3.6 mmHg,且与血管扩张和交感激活严重程度直接相关。
  • NSBBs在两组中均相似降低心率和HVPG,但RA组EIVPD降低20%,DRA组仅降低2%(p<0.01)。
  • RA组NSBBs诱导的EIVPD降低与血管扩张严重程度及更高的血浆一氧化氮、去甲肾上腺素和IL-6相关(r>0.40,均p<0.05)。
  • NSBBs降低两组RPP,但仅RA患者肾功能受损;EIVPD降低与RPP和eGFR下降相关(r>0.40,均p<0.01)。
  • NSBBs治疗后,20例RA患者中11例(55%)RPP降至肾血流自动调节阈值以下,包括4例符合HRS-AKI标准者。

临床怎么用

  • 对难治性腹水肝硬化患者,使用非选择性β受体阻滞剂前应评估肾功能和血流动力学风险。
  • 难治性腹水患者使用NSBBs期间需密切监测肾功能和肾灌注压相关指标。
  • 难治性腹水患者应考虑慎用甚至避免β受体阻滞剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The safety of non-selective β-blockers (NSBBs) has been questioned in refractory ascites (RA). We studied the effects of NSBBs on cardiac systolic function, systemic hemodynamics, and renal perfusion pressure (RPP) and function in patients with diuretic-responsive ascites (DRA) and RA. METHODS: We performed a prospective pre-post repeated-measures study in cirrhotic patients, 18 with DRA and 20 with RA on NSBBs for variceal bleeding prophylaxis. Systolic function (by ejection intraventricular pressure difference [EIVPD]), hepatic venous pressure gradient (HVPG), cardiopulmonary pressures, RPP, and sympathetic activation were measured at baseline and after 4 weeks of propranolol. RESULTS: EIVPD was elevated at baseline (RA 4.5 [2.8-5.7] and DRA 4.2 [3.1-5.7] mmHg; normal 2.4-3.6 mmHg) and directly related to the severity of vasodilation and sympathetic activation. NSBBs led to similar reductions in heart rate and HVPG in both groups. NSBBs reduced EIPVD in RA but not in DRA (-20% vs. -2%, p <0.01). In RA, the NSBB-induced reduction in EIPVD correlated with the severity of vasodilation and with higher plasma nitric oxide, norepinephrine and IL-6 (r >0.40, all p <0.05). NSBBs reduced RPP in both groups, but impaired renal function only in patients with RA. Reduced EIPVD correlated with decreases in RPP and estimated glomerular filtration rate (r >0.40, all p <0.01). After NSBB treatment, RPP dropped below the threshold of renal flow autoregulation in 11 of the 20 (55%) patients with RA, including the 4 fulfilling the criteria for HRS-AKI. CONCLUSION: Renal perfusion and function depend critically on systolic function and sympathetic hyperactivation in RA. NSBBs blunt the sympathetic overdrive, hamper cardiac output, lower RPP below the critical threshold and impair renal function. β-blockade should be used cautiously or even avoided in patients with RA. LAY SUMMARY: We have identified the mechanisms by which non-selective beta-blockers could impair survival in patients with refractory ascites. We show that peripheral vasodilation and sympathetic activation lead to increased left ventricle systolic function in patients with cirrhosis and ascites, which acts as an adaptive mechanism to maintain renal perfusion. When ascites becomes refractory, this compensatory cardiac response to vasodilation is critically dependent on sympathetic hyperactivation and is hardly able to maintain renal perfusion. In this setting, β-blockade blunts the sympathetic overdrive of cardiac function, hampers cardiac output, lowers renal perfusion pressure below the critical threshold and impairs renal function.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C, et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol. 2020. PMID: 32446716. doi:10.1016/j.jhep.2020.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。